Valorum

Valorum Biologics is a biotechnology company focused on the development and commercialization of high-quality biosimilars to increase global access to life-saving biologic medicines. The company targets large therapeutic areas, including ophthalmology, immunology, and oncology, by providing more affordable alternatives to expensive reference products. Valorum leverages a strategic partnership model, notably collaborating with global pharmaceutical firms like Lupin to bring biosimilar candidates through clinical development and regulatory approval. Their portfolio includes biosimilar versions of major biologics such as ranibizumab and adalimumab. By focusing on efficient development and commercialization strategies, Valorum aims to reduce healthcare costs while maintaining the highest standards of drug safety and efficacy. The company is headquartered in the United States and operates with a lean, expert-led organizational structure.